Discovery of the imidazole-derived GPR40 agonist AM-3189.
San Francisco, United States. In Bioorg Med Chem Lett, Feb 2016
As a follow-up to the GPR40 agonist AMG 837, which was evaluated in clinical trials for the treatment of type II diabetes, further optimization led to the discovery of AM-3189 (13k).
New Insights into the High-Density Lipoprotein Dilemma.
Houston, United States. In Trends Endocrinol Metab, Jan 2016
We propose here that the cardioprotective effects of alcohol are mediated by the interaction of its terminal metabolite, acetate, with the adipocyte free fatty acid receptor 2 (FFAR2), which elicits a profound antilipolytic effect that may increase insulin sensitivity without necessarily raising plasma HDL-C concentration.